194 related articles for article (PubMed ID: 28711713)
1. Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.
Elfgen A; Santiago-Schübel B; Gremer L; Kutzsche J; Willbold D
Eur J Pharm Sci; 2017 Sep; 107():203-207. PubMed ID: 28711713
[TBL] [Abstract][Full Text] [Related]
2. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species.
Ziehm T; Brener O; van Groen T; Kadish I; Frenzel D; Tusche M; Kutzsche J; Reiß K; Gremer L; Nagel-Steger L; Willbold D
ACS Chem Neurosci; 2016 Aug; 7(8):1088-96. PubMed ID: 27240424
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.
Jiang N; Leithold LH; Post J; Ziehm T; Mauler J; Gremer L; Cremer M; Schartmann E; Shah NJ; Kutzsche J; Langen KJ; Breitkreutz J; Willbold D; Willuweit A
PLoS One; 2015; 10(6):e0128553. PubMed ID: 26046986
[TBL] [Abstract][Full Text] [Related]
4. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease.
Kutzsche J; Schemmert S; Tusche M; Neddens J; Rabl R; Jürgens D; Brener O; Willuweit A; Hutter-Paier B; Willbold D
Molecules; 2017 Oct; 22(10):. PubMed ID: 28994710
[TBL] [Abstract][Full Text] [Related]
5. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers.
Elfgen A; Hupert M; Bochinsky K; Tusche M; González de San Román Martin E; Gering I; Sacchi S; Pollegioni L; Huesgen PF; Hartmann R; Santiago-Schübel B; Kutzsche J; Willbold D
Sci Rep; 2019 Apr; 9(1):5715. PubMed ID: 30952881
[TBL] [Abstract][Full Text] [Related]
6. Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.
Jiang N; Frenzel D; Schartmann E; van Groen T; Kadish I; Shah NJ; Langen KJ; Willbold D; Willuweit A
Biochim Biophys Acta; 2016 Nov; 1858(11):2717-2724. PubMed ID: 27423267
[TBL] [Abstract][Full Text] [Related]
7. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2.
Schemmert S; Schartmann E; Honold D; Zafiu C; Ziehm T; Langen KJ; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neurobiol Dis; 2019 Apr; 124():36-45. PubMed ID: 30391539
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease.
Schartmann E; Schemmert S; Niemietz N; Honold D; Ziehm T; Tusche M; Elfgen A; Gering I; Brener O; Shah NJ; Langen KJ; Kutzsche J; Willbold D; Willuweit A
J Alzheimers Dis; 2018; 64(3):859-873. PubMed ID: 29966196
[TBL] [Abstract][Full Text] [Related]
9. Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.
Aileen Funke S; van Groen T; Kadish I; Bartnik D; Nagel-Steger L; Brener O; Sehl T; Batra-Safferling R; Moriscot C; Schoehn G; Horn AH; Müller-Schiffmann A; Korth C; Sticht H; Willbold D
ACS Chem Neurosci; 2010 Sep; 1(9):639-48. PubMed ID: 22778851
[TBL] [Abstract][Full Text] [Related]
10. Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination.
Klein AN; Ziehm T; Tusche M; Buitenhuis J; Bartnik D; Boeddrich A; Wiglenda T; Wanker E; Funke SA; Brener O; Gremer L; Kutzsche J; Willbold D
PLoS One; 2016; 11(4):e0153035. PubMed ID: 27105346
[TBL] [Abstract][Full Text] [Related]
11. Aβ oligomer eliminating compounds interfere successfully with pEAβ(3-42) induced motor neurodegenerative phenotype in transgenic mice.
Dunkelmann T; Teichmann K; Ziehm T; Schemmert S; Frenzel D; Tusche M; Dammers C; Jürgens D; Langen KJ; Demuth HU; Shah NJ; Kutzsche J; Willuweit A; Willbold D
Neuropeptides; 2018 Feb; 67():27-35. PubMed ID: 29273382
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
Leithold LH; Jiang N; Post J; Ziehm T; Schartmann E; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Pharm Res; 2016 Feb; 33(2):328-36. PubMed ID: 26381279
[TBL] [Abstract][Full Text] [Related]
13. Structures of the amyloid β-peptides Aβ1-40 and Aβ1-42 as influenced by pH and a D-peptide.
Olubiyi OO; Strodel B
J Phys Chem B; 2012 Mar; 116(10):3280-91. PubMed ID: 22300010
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.
Leithold LH; Jiang N; Post J; Niemietz N; Schartmann E; Ziehm T; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Eur J Pharm Sci; 2016 Jun; 89():31-8. PubMed ID: 27086111
[TBL] [Abstract][Full Text] [Related]
15. Differently selected D-enantiomeric peptides act on different Abeta species.
Bartnik D; Funke SA; Andrei-Selmer LC; Bacher M; Dodel R; Willbold D
Rejuvenation Res; 2010; 13(2-3):202-5. PubMed ID: 19954333
[TBL] [Abstract][Full Text] [Related]
16. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
Schartmann E; Schemmert S; Ziehm T; Leithold LHE; Jiang N; Tusche M; Joni Shah N; Langen KJ; Kutzsche J; Willbold D; Willuweit A
Eur J Pharm Sci; 2018 Mar; 114():93-102. PubMed ID: 29225107
[TBL] [Abstract][Full Text] [Related]
17. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid.
Elfgen A; Santiago-Schübel B; Hupert M; Schemmert S; Schartmann E; Tusche M; Gering I; Zafiu C; Kutzsche J
Eur J Pharm Sci; 2021 Jan; 156():105581. PubMed ID: 33035662
[TBL] [Abstract][Full Text] [Related]
18. Role of Hydrophobicity and Charge of Amyloid-Beta Oligomer Eliminating d-Peptides in the Interaction with Amyloid-Beta Monomers.
Ziehm T; Buell AK; Willbold D
ACS Chem Neurosci; 2018 Nov; 9(11):2679-2688. PubMed ID: 29893543
[TBL] [Abstract][Full Text] [Related]
19. All
Bocharov EV; Gremer L; Urban AS; Okhrimenko IS; Volynsky PE; Nadezhdin KD; Bocharova OV; Kornilov DA; Zagryadskaya YA; Kamynina AV; Kuzmichev PK; Kutzsche J; Bolakhrif N; Müller-Schiffmann A; Dencher NA; Arseniev AS; Efremov RG; Gordeliy VI; Willbold D
J Med Chem; 2021 Nov; 64(22):16464-16479. PubMed ID: 34739758
[TBL] [Abstract][Full Text] [Related]
20. Transport of Alzheimer disease amyloid-beta-binding D-amino acid peptides across an in vitro blood-brain barrier model.
Liu H; Funke SA; Willbold D
Rejuvenation Res; 2010; 13(2-3):210-3. PubMed ID: 19954305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
